Almirall Strikes Again In Derma
This article was originally published in Scrip
Executive Summary
Barcelona based Almirall has signed an agreement to acquire dermatology focused Poli Group holding, another move in Almirall's grand plan to become a dermatology specialist.
You may also be interested in...
Mid-Sized European Companies Eager to Acquire During Growth Spurt
Among Europe’s flourishing niche of mid-sized pharmaceutical companies, Italy’s Recordati and Spain’s Almirall have snapped up smaller local companies during the past six to nine months, while Switzerland’s Actelion is concentrating on executing new product launches while considering M&A.
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.